78
Participants
Start Date
October 14, 2024
Primary Completion Date
September 30, 2027
Study Completion Date
June 30, 2028
Cessation of somatostatin analogues
Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
Continuation of somatostatin analogues
Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
RECRUITING
Royal North Shore Hospital, Sydney
RECRUITING
Wollongong Hospital, Wollongong
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Royal Brisbane and Womens Hospital, Brisbane
RECRUITING
The Queen Elizabeth Hospital, Adelaide
RECRUITING
Fiona Stanley Hospital, Perth
RECRUITING
BC Cancer Agency, Vancouver Cancer Centre, Vancouver
RECRUITING
London Health Sciences Centre Research Institute (LHSCRI), London
RECRUITING
Ottawa Hospital Research Institute, Ottawa
RECRUITING
Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto
RECRUITING
Allan Blair Cancer Centre, Regina
RECRUITING
Saskatoon Cancer Centre, Saskatoon
Canadian Cancer Trials Group
NETWORK
Australasian Gastro-Intestinal Trials Group
NETWORK